1. Introduction {#sec1-ijms-21-00123}
===============

*Leptin* is a peptide hormone composed of 167 amino acids. It is mainly produced in the adipose tissue but could also be found in the placenta, mammary gland, and other body tissues \[[@B1-ijms-21-00123]\]. Its major role in glucose metabolism was demonstrated in 1995 on ob/ob (*leptin-*deficient) mice that were extremely obese and diabetic \[[@B2-ijms-21-00123]\]. *LEP* is a marker for energy storage and body weight; circulating *LEP* levels are proportional to body fat content \[[@B3-ijms-21-00123],[@B4-ijms-21-00123]\]. Despite the high levels of *LEP* and energy stores in obese individuals, sensitivity to *lep*tin is decreased, resulting in an inability to detect satiety \[[@B5-ijms-21-00123]\]. Energy deficiencies are associated with decreased *LEP* levels and *LEP* receptor activation in the arcuate nucleus of the hypothalamus \[[@B6-ijms-21-00123]\].

Osteoarthritis also called degenerative joint disease is the commonest form of arthritis and is the main cause of pain, disability, and poor quality of life among older adults \[[@B7-ijms-21-00123],[@B8-ijms-21-00123]\]. In Taiwan, about 37 % of individuals over 50 years old have OA \[[@B7-ijms-21-00123]\]. Obesity is a well-established risk factor for OA \[[@B9-ijms-21-00123]\]. The risk of OA higher in type 2 diabetic patients and obese individuals with metabolic syndrome \[[@B8-ijms-21-00123]\].

*LEP* is one of the main regulators of osteoarthritis pathogenesis \[[@B10-ijms-21-00123],[@B11-ijms-21-00123],[@B12-ijms-21-00123],[@B13-ijms-21-00123]\]. In a study conducted in China, serum *LEP* levels were significantly higher in osteoarthritic patients with or without metabolic syndrome, suggesting the regulatory role of *LEP* in OA progression \[[@B10-ijms-21-00123]\]. *LEP* levels were also higher in the cartilage of osteoarthritic individuals than in those without OA \[[@B10-ijms-21-00123],[@B14-ijms-21-00123]\]. *LEP* enhances osteoarthritis development by exerting pro-inflammatory and pro-catabolic actions on the cartilage, leading to articular degeneration which is typical of osteoarthritis \[[@B15-ijms-21-00123]\]. High levels of *LEP* expressions promote the synthesis and expression of nitric oxide, matrix metalloprotease-9, and matrix metalloprotease-13 in chondrocytes, thereby affecting their functions which could finally result in osteoarthritis \[[@B11-ijms-21-00123],[@B16-ijms-21-00123]\]. Systemic inflammatory impacts of adipokines including *LEP*, resistin, and adiponectin (ADIPO) among others mediate the relationship between obesity and osteoarthritis \[[@B17-ijms-21-00123],[@B18-ijms-21-00123]\].

Recently, several researchers have explored genetic and epigenetic processes including single nucleotide polymorphism (SNP), methylation, and expression of *LEP* in obesity and OA \[[@B11-ijms-21-00123],[@B19-ijms-21-00123],[@B20-ijms-21-00123],[@B21-ijms-21-00123],[@B22-ijms-21-00123],[@B23-ijms-21-00123]\]. For instance, in Wistar National Institute of Nutrition (WNIN) obese mutant rats, *LEP* methylation levels, and transcription levels were positively correlated, suggesting a complex and dynamic underlying epigenetic mechanism for aberrant *LEP* expression in obesity \[[@B20-ijms-21-00123]\]. *LEP* promoter methylation is associated with gene expression \[[@B24-ijms-21-00123]\]. Moreover, it is tissue-specific and differs in different stages of development in humans \[[@B25-ijms-21-00123],[@B26-ijms-21-00123]\]. For instance, *LEP* promoter methylation levels in human chondrocytes were inversely correlated with *LEP* expression, with advanced osteoarthritic chondrocytes being more highly expressed than the minimally osteoarthritic and normal chondrocytes \[[@B12-ijms-21-00123]\]. Moreover, *LEP* levels were significantly higher in advanced osteoarthritic cartilage compared to minimally osteoarthritic cartilage \[[@B13-ijms-21-00123]\].

So far, few studies have been conducted to determine the interaction between BMI and osteoarthritis on *LEP* methylation. This study was conducted to investigate the interaction of BMI with osteoarthritis on *LEP* promoter methylation.

2. Results {#sec2-ijms-21-00123}
==========

[Table 1](#ijms-21-00123-t001){ref-type="table"} shows the basic characteristics of the study participants stratified by OA status. There were 1141 participants comprising 48 osteoarthritic and 1093 non-osteoarthritic cases. The mean ± standard error (SE) *LEP* promoter methylation level in osteoarthritic cases was 0.5509 ± 0.00437 and was significantly higher (*p*-value = 0.0064) than that (0.5375 ± 0.00101) in the non-cases. In addition, the ages of the cases were significantly different from those of the non-cases (*p*-value \< 0.0001). However, BMI, sex, waist-hip ratio, exercise, smoking, alcohol drinking, diabetes, and hypertension were not significantly different between the osteoarthritic cases and non-osteoarthritic cases ([Table 1](#ijms-21-00123-t001){ref-type="table"}).

Results of logistic regression analysis revealed no significant association of OA and BMI with *LEP* promoter methylation ([Table 2](#ijms-21-00123-t002){ref-type="table"}). However, age was significantly associated with higher levels of *LEP* gene promoter methylation. The regression coefficients (*β*); *p*-value were 0.00931; 0.0002, 0.01984; \<0.001, and 0.02581; \<0.0001, for the age groups 41--50, 51--60, and 61--70 years, respectively ([Table 2](#ijms-21-00123-t002){ref-type="table"}).

Even though the association of OA and BMI with *LEP* promoter methylation was not significant, a significant interaction (*p*-value = 0.018) between OA and BMI on *LEP* promoter methylation was observed ([Table 3](#ijms-21-00123-t003){ref-type="table"}). After stratification by OA status, BMI was significantly associated with *LEP* promoter methylation only in osteoarthritic individuals ([Table 3](#ijms-21-00123-t003){ref-type="table"}); obesity was significantly associated with higher levels of *LEP* promoter methylation in osteoarthritic individuals (*β* = 0.03696; *p*-value = 0.0187). In addition, overweight was associated (borderline significance) with higher *LEP* promoter methylation; *β* = 0.02045 and *p*-value = 0.536 ([Table 3](#ijms-21-00123-t003){ref-type="table"}).

3. Discussion {#sec3-ijms-21-00123}
=============

To the best of our knowledge, this is the first study to investigate the interaction between BMI and osteoarthritis on *LEP* promoter methylation. In osteoarthritic patients, the mean *LEP* promoter methylation level was significantly higher in obese individuals. However, in non-osteoarthritic individuals, BMI was not significantly associated with *LEP* promoter methylation.

*LEP* promoter methylation is associated with gene expression \[[@B24-ijms-21-00123]\]. In WNIN obese mutant rats, *LEP* methylation levels and transcription were positively correlated, suggesting a complex and dynamic underlying epigenetic mechanism for aberrant *LEP* expression in obesity \[[@B20-ijms-21-00123]\]. In humans, *LEP* methylation levels were inversely correlated with gene expression \[[@B12-ijms-21-00123]\]. In this regard, we assume that serum *LEP* levels in obese osteoarthritic individuals (whose *LEP* promoter methylation levels were significantly higher) could be lower than the levels in normal-weight osteoarthritic individuals. Generally, *LEP* levels are positively correlated with adiposity and are usually elevated in obese individuals \[[@B4-ijms-21-00123],[@B27-ijms-21-00123],[@B28-ijms-21-00123],[@B29-ijms-21-00123]\]. However, low *LEP* levels have also been found to be associated with weight gain. For example, in a longitudinal study conducted on obese Pima Indians, participants who gained weight had lower mean plasma *LEP* levels compared to those with a stable weight, suggesting the positive association of low *LEP* levels with weight gain and obesity \[[@B30-ijms-21-00123]\]. In addition, results from reanalyzes of data from previous clinical trials showed that obese individuals with low levels of *LEP* lost more weight after treatment with *LEP* analog (metreleptin), compared with the placebo. As such, using low *LEP* levels as biomarkers, *LEP* analogs or other receptor agonists could be developed as obesity therapy in a subgroup of obese individuals \[[@B31-ijms-21-00123]\]. In this regard, the obese osteoarthritic individuals in our study assumed to have low levels of *leptin* might have a better response (reduced weight) to *leptin* therapy, compared with those with higher levels of *leptin*. Hence, OA could be indirectly targeted in individuals with low *leptin* levels by treating obesity which is its major risk factor \[[@B9-ijms-21-00123]\]. Since epigenetic processes are reversible, epigenetic therapy has also been suggested as a possible therapeutic potential for the treatment of osteoarthritis \[[@B12-ijms-21-00123]\]. Hence, methylation-associated osteoarthritis could be epigenetically managed with DNA methylation inhibitors.

Most studies have demonstrated that serum *leptin* levels in people with osteoarthritis are high \[[@B10-ijms-21-00123],[@B15-ijms-21-00123],[@B32-ijms-21-00123]\]. In our study, *LEP* promoter methylation levels were higher in obese individuals with osteoarthritis. Aside from DNA methylation, transcription factors and SNP are also believed to influence *LEP* gene expression \[[@B11-ijms-21-00123],[@B19-ijms-21-00123],[@B22-ijms-21-00123]\]. In addition, factors like insulin and *leptin* receptors and resistance also influence the serum levels of *leptin* \[[@B1-ijms-21-00123],[@B33-ijms-21-00123],[@B34-ijms-21-00123]\]. However, it was beyond the scope of our study to explore all the complex processes that could affect the expression and function of *LEP* in OA.

The current advancement in precision medical research has paved the way to explore aging and epigenetic modification of aging-related genes \[[@B35-ijms-21-00123]\]. For instance, serum levels of *LEP* were found to be high in aging and obesity-related diseases like obstructive sleep apnea (OSA) and Alzheimer's disease \[[@B36-ijms-21-00123],[@B37-ijms-21-00123]\]. Moreover, lower levels of *LEP* promoter methylation were associated with anorexia nervosa (AN) \[[@B38-ijms-21-00123]\]. These show the importance of *leptin* in the regulation of aging and aging-related diseases. Osteoarthritis and obesity are two prevalent aging health problems in the world \[[@B39-ijms-21-00123]\]. As previously stated, the incidence of osteoarthritis in obese individuals is high \[[@B32-ijms-21-00123]\]. Our findings suggest that *LEP* methylation might be involved in the pathogenesis of osteoarthritis. According to the United Nations classification, Taiwan is an aging society \[[@B40-ijms-21-00123]\]. The percentage of adults over 65 years old in Taiwan is forecast to surpass 20% by 2025 \[[@B7-ijms-21-00123]\].

Even though LEP methylation data are available in the Taiwan Biobank Database, data on serum levels of LEP are not available in the database. As such, we could not assess the serum levels of LEP in the participants. This is a limitation of our study.

4. Materials and Methods {#sec4-ijms-21-00123}
========================

4.1. Data Source {#sec4dot1-ijms-21-00123}
----------------

All the data used in this study were retrieved from the Taiwan Biobank database (2008--2015). Enrollment in the Taiwan biobank is restricted to Taiwanese who are 30 to 70 years old without a personal history of cancer \[[@B41-ijms-21-00123]\].

4.2. Study Participants {#sec4dot2-ijms-21-00123}
-----------------------

A total of 1141 individuals (583 men and 558 women) were eligible for this study. Their demographic data including sex, age, body mass index (BMI), and waist-hip ratio (WHR); lifestyle data (regular exercise, smoking, and alcohol consumption); disease history (diabetes and hypertension), and genetic information (*LEP* methylation) were obtained from the Taiwan Biobank Database. Information on osteoarthritis was self-reported and participants were grouped into two: non-cases were those who reported no prior clinical diagnosis of osteoarthritis while cases were those who reported having ever been clinically diagnosed with osteoarthritis. BMI categories included underweight (BMI \< 18.5 kg/m^2^), normal weight (18.5 ≤ BMI \< 24 kg/m^2^), overweight (24 ≤ BMI \< 27 kg/m^2^), obesity (BMI ≥ 27 kg/m^2^).

4.3. DNA Methylation Analysis {#sec4dot3-ijms-21-00123}
-----------------------------

DNA methylation assessment was performed on sodium bisulfite-treated DNA from whole blood using the Infinium^®^ MethylationEPIC BeadChipEPIC array (Illumina Inc. San Diego, CA, USA). The following quality control measures were taken: (1) correction for dye-bias across batches by normalization, (2) removal of background signals, (3) elimination of outliers by the median absolute deviation method, and (4) elimination of probes with poor detection (*p*-value \> 0.05) and those whose bead counts were \< 3. The Chung Shan Medical University Institutional Review Board (CS2-17070) approved this study.

4.4. Statistical Analysis {#sec4dot4-ijms-21-00123}
-------------------------

The SAS 9.4 software (SAS Institute, Cary, NC, USA) was used for data management and analysis. T-test was used to compare the mean *LEP* promoter methylation levels in osteoarthritic and non-osteoarthritic participants and the results were presented as mean ± standard error (SE). Chi-square test was used to compare the categorical variables between the osteoarthritic and non-osteoarthritic cases and the results were presented as percentages. Multivariate linear regression models were used to determine the association of osteoarthritis and BMI with *LEP* promoter methylation and the interaction between osteoarthritis and BMI on *LEP* promoter methylation. Because whole blood was used to determine DNA methylation, the Reference-Free Adjustment for Cell-Type composition (ReFACTor) method was used to adjust for cell-type heterogeneity \[[@B42-ijms-21-00123]\].

5. Conclusions {#sec5-ijms-21-00123}
==============

BMI was significantly associated with higher *LEP* promoter methylation levels in individuals with osteoarthritis. This association was particularly prominent in obese osteoarthritic individuals.
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ijms-21-00123-t001_Table 1

###### 

Basic characteristics of participants stratified by osteoarthritis status.

  -----------------------------------------------------------------------------------
  Variable                   Without Osteoarthritis\   Osteoarthritis\    *p*-Value
                             (*n* = 1093)              (*n* = 48)         
  -------------------------- ------------------------- ------------------ -----------
  *LEP* promoter mean        0.5375 ± 0.00101          0.5509 ± 0.00437   0.0064

  BMI (kg/m^2^)                                                           0.5978

  Normal                     516(47.21)                24(50.00)          

  Underweight                36(3.29)                  0(0.00)            

  Overweight                 319(29.19)                13(27.08)          

  Obese                      222(20.31)                11(22.92)          

  Sex                                                                     0.8767

  Men                        534(48.86)                24(50.00)          

  Women                      559(51.14)                24(50.00)          

  Age                                                                     \<0.0001

  30--40                     286(26.17)                2(4.17)            

  41--50                     281(25.71)                5(10.42)           

  51--60                     327(29.92)                14(29.17)          

  61--70                     199(18.21)                27(56.25)          

  Waist-hip ratio                                                         0.1070

  Men \< 0.9; women \< 0.8   470(43.00)                15(31.25)          

  men ≥ 0.9; women ≥ 0.8     623(57.00)                33(68.75)          

  Exercise                                                                0.0422

  No                         618(56.54)                20(41.67)          

  Yes                        475(43.46)                28(58.33)          

  Smoking                                                                 0.1175

  Never                      815(74.57)                38(79.17)          

  Quit                       156(14.27)                9(18.75)           

  Current                    122(11.16)                1(2.08)            

  Drinking                                                                0.4099

  Never                      980(89.66)                45(93.75)          

  Quit                       37(3.39)                  2(4.17)            

  Current                    76(6.95)                  1(2.08)            

  Diabetes                                                                0.0816

  No                         993(90.85)                40(83.33)          

  Yes                        100(9.15)                 8(16.67)           

  Hypertension                                                            0.2351

  No                         874(79.96)                35(72.92)          

  Yes                        219(20.04)                13(27.08)          
  -----------------------------------------------------------------------------------

ijms-21-00123-t002_Table 2

###### 

Multiple linear regression showing the association of *LEP* promoter methylation with osteoarthritis and BMI.

  Variable                                                  *β*        *p*-Value
  --------------------------------------------------------- ---------- -----------
  Osteoarthritis (reference: no)                                       
  Yes                                                       0.00107    0.8097
  BMI (reference: normal)                                              
  Underweight                                               −0.00363   0.4820
  Overweight                                                −0.00128   0.5497
  Obese                                                     −0.00198   0.4349
  Sex (reference: women)                                               
  Men                                                       −0.00041   0.8502
  Age (reference: 30--40)                                              
  41--50                                                    0.00931    0.0002
  51--60                                                    0.01984    \<0.0001
  61--70                                                    0.02581    \<0.0001
  Waist-hip ratio (reference: male \< 0.9; female \< 0.8)              
  Men ≥ 0.9; women ≥ 0.8                                    −0.00161   0.4389
  Exercise (reference: no)                                             
  Yes                                                       −0.00148   0.4347
  Smoking (reference: never)                                           
  Quit                                                      0.00029    0.9148
  Current                                                   0.00159    0.6063
  Drinking (reference: never)                                          
  Quit                                                      0.00402    0.4184
  Current                                                   −0.00556   0.1302
  Diabetes (reference: no)                                             
  Yes                                                       0.00099    0.7544
  Hypertension (reference: no)                                         
  Yes                                                       −0.00001   0.9973

ijms-21-00123-t003_Table 3

###### 

Multiple linear regression showing the association between *LEP* promoter methylation and BMI stratified by osteoarthritis status.

  Variable                                                  Without Osteoarthritis   Osteoarthritis              
  --------------------------------------------------------- ------------------------ ---------------- ---------- --------
  BMI (reference: normal)                                                                                        
  Underweight                                               −0.00365                 0.4803           \-         \-
  Overweight                                                −0.00241                 0.2739           0.02045    0.0536
  Obese                                                     −0.00311                 0.2306           0.03696    0.0187
  Sex (reference: female)                                                                                        
  Male                                                      0.00018                  0.9341           −0.01712   0.1392
  Age (reference: 30--40)                                                                                        
  41--50                                                    0.00907                  0.0004           0.01646    0.5695
  51--60                                                    0.01993                  \<.0001          0.01252    0.6110
  61--70                                                    0.02544                  \<.0001          0.03016    0.2206
  Waist-hip ratio (reference: male \< 0.9; female \< 0.8)                                                        
  Men ≥ 0.9; women ≥ 0.8                                    −0.00115                 0.5853           −0.01395   0.2546
  Exercise (reference: no)                                                                                       
  Yes                                                       −0.00127                 0.5111           −0.00193   0.8479
  Smoking (reference: never)                                                                                     
  Quit                                                      0.00009                  0.9737           0.00112    0.9352
  Current                                                   0.00199                  0.5226           −0.04526   0.1564
  Drinking (reference: never)                                                                                    
  Quit                                                      0.00211                  0.6807           0.04499    0.0456
  Current                                                   −0.00580                 0.1182           −0.01202   0.6944
  Diabetes (reference: no)                                                                                       
  Yes                                                       0.00151                  0.6462           0.00381    0.7518
  Hypertension (reference: no)                                                                                   
  Yes                                                       −0.00020                 0.9340           0.01222    0.2126
  Osteoarthritis \* BMI interaction                         *p*-value = 0.0180                                   

\- signifies no available data.
